An ongoing basket phase II study (NCT03682289) is currently evaluating the combination of ceralasertib and olaparib in multiple tumour types, including prostate cancer; this trial includes a subgroup of 20 patients with ATM loss (10 with mCRPC) [79]. Here, ATM is linked to neoplasm.